Targeted Onc
@TargetedOnc
Connecting community oncology with emerging science, actionable insights & peer perspectives to advance patient care.
加入 July 2012
3.5K 正在關注 21.1K 粉絲
At #ESMO26#, @DrDarrenFeldman (@MSKCancerCenter) discusses phase 1 data showing ixotatug vedotin drives notable responses in heavily pretreated #GermCellTumors#, with manageable ADC safety and potential phase 2 plans.
🎥 WATCH:
#Oncology# #CancerTreatment#
顯示更多
